ACXP Acurx Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1736243 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY11.7%
TTM EPS YoY76.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-147.5%
ROA-98.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets29.0%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-15.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.12M | $1.07M | $341,468 | $281,807 | $429,691 | $524,210 | $598,798 | $825,059 |
| SG&A expense | $1.52M | $1.24M | $1.37M | $1.34M | $1.60M | $1.75M | $1.58M | $1.97M |
| Operating income | -$2.63M | -$2.31M | -$1.72M | -$1.62M | -$2.03M | -$2.27M | -$2.18M | -$2.79M |
| Net income | -$2.58M | -$2.25M | -$1.68M | -$1.58M | -$1.99M | -$2.25M | -$2.15M | -$2.78M |
| EPS (basic) | -0.49 | -0.53 | -0.62 | — | -1.23 | -1.89 | -2.15 | — |
| EPS (diluted) | -0.49 | -0.53 | -0.62 | — | -1.23 | -1.89 | -2.15 | — |
| Weighted avg. shares (diluted) | 5.32M | 4.26M | 2.72M | — | 1.63M | 1.19M | 1.00M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $9.65M | $10.66M | $9.25M | $7.56M | $5.91M | $6.06M | $4.64M | $3.71M |
| Current assets | — | — | — | — | — | $6.16M | $4.81M | $3.86M |
| Total assets | $10.34M | $10.98M | $9.54M | $7.69M | $6.11M | — | — | $3.86M |
| Current liabilities | $2.99M | $2.83M | $2.53M | $2.42M | $2.47M | $2.59M | $2.49M | $3.24M |
| Total liabilities | $2.99M | $2.83M | $2.53M | $2.42M | $2.47M | $2.59M | $2.49M | $3.24M |
| Shareholders' equity | $7.34M | $8.15M | $7.01M | $5.27M | $3.64M | $3.57M | $2.31M | $615,121 |
| Shares outstanding | 5.88M | 4.68M | 3.39M | 2.35M | 1.80M | 1.47M | 22.40M | 851,534 |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.49M | -$1.71M | -$1.41M | -$1.18M | -$1.88M | -$1.67M | -$2.05M | -$2.25M |
| Financing cash flow | $1.49M | $3.11M | $3.11M | $2.83M | $1.72M | $3.09M | $2.99M | $194,547 |
| Stock-based compensation | $208,169 | $200,537 | $258,287 | $294,794 | $294,793 | $324,216 | $333,598 | $345,191 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.